Jul 30,2021

Virtual Group Appointments Reduce Distress and Improve Care Management in Young Adults with Type 1 Diabetes

The purpose of this study was to analyze the impact of virtual group appointments (VGA) on self-reported health-related outcomes and care activities for young adults (YA) with type 1 diabetes (T1D).

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Aug 31,2021

Live stream event 2021: "Beurer HealthManager Pro": The new app for holistic health management

Whether at home, at the doctor's or on the go - today health data should be available and shareable at all times. With its Connect products, Beurer keeps setting trends in digital health care and motivates people to be more health conscious in everyday life. With the new "beurer HealthManager Pro" app, Beurer is launching a medical device app that takes modern health management to a new level.

View Analyst & Ambassador Comments
Go to original news
Aug 05,2021

MyWay Digital Health proud to be part of the AI accelerator programme which has helped tech start ups raise over £6m

Fifteen tech start-ups have raised £6.3 million in investment and grants after taking part in a new AI accelerator programme set up by the University of Edinburgh.

View Analyst & Ambassador Comments
Go to original news
Aug 02,2021

Brighter receives clarification from the United Arab Emirates Ministry of Health and Prevention regarding data storage and processing in Actiste® Diabetes Management Solution

Brighter AB (Publ) (“Brighter” or “the Company”) announced today that the United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has notified the Company of a preliminary assessment clarifying certain matters relating to data storage and processing in Actiste® Diabetes Management Solution.

PRODUCT

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Aug 02,2021

ABBOTT'S FREESTYLE® LIBRE 2 IOS APP CLEARED IN U.S., PROVIDING A SEAMLESS DIGITAL EXPERIENCE TO SIMPLIFY DIABETES MANAGEMENT

Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible iPhones1, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Providing breakthrough technology that is accessible and affordable4, the FreeStyle Libre portfolio is the number one continuous glucose monitoring (CGM) system worldwide5 and most prescribed in the U.S.6, changing the lives of nearly 3.5 million people across more than 50 countries including 1 million users in the U.S.

REGULATORY FDA

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 04,2021

DayTwo Announces New CEO and Raises $37 Million For Expansion of Chronic Disease Solutions

David Henderson, former founding executive member of Oscar Health, has been appointed as Chief Executive Officer of DayTwo. He joins to further scale the company and expand solutions for employers, health plans, and health systems. DayTwo also announced $37 million in new funding to accelerate its expansion of chronic disease interventions.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 04,2021

Tandem Diabetes Care Announces Second Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2021 and updated its sales guidance for the year ending December 31, 2021.

View Analyst & Ambassador Comments
Go to original news
Aug 05,2021

Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year

Second quarter 2021 revenue of $263.2 million, up 16.3%, or 12.5% in constant currency1, compared to $226.3 million in the prior year, within the guidance range of 10% to 14% on a constant currency basis

View Analyst & Ambassador Comments
Go to original news
Aug 05,2021

BD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021

BD, a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the third fiscal quarter ended June 30, 2021. This represents a year-over-year increase of 26.9% on a reported basis and 22.0% on a currency-neutral basis. The increase is primarily driven by the strong base business performance as overall healthcare utilization levels continued to recover from the initial impact of COVID-19.

View Analyst & Ambassador Comments
Go to original news
Aug 09,2021

Senseonics Holdings, Inc. Reports Second Quarter 2021 Financial Results

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2021.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES